{Reference Type}: Journal Article
{Title}: Quetiapine Significantly Improves the Effectiveness of Radiotherapy in Combating Hepatocellular Carcinoma Progression in a Hep3B Xenograft Mouse Model.
{Author}: Yang JD;Liu YC;Wang HC;Hsu FT;Liao TL;Huang MC;Chen JH;
{Journal}: In Vivo
{Volume}: 38
{Issue}: 3
{Year}: 2024 May-Jun
{Factor}: 2.406
{DOI}: 10.21873/invivo.13542
{Abstract}: <B>OBJECTIVE: </B>In hepatocellular carcinoma (HCC) treatment, radiotherapy (RT) stands as a pivotal approach, yet the emergence of radioresistance poses a formidable challenge. This study aimed to explore the potential synergy between quetiapine and RT for HCC treatment.<BR><B>METHODS: </B>A Hep3B xenograft mouse model was used, the investigation tracked tumor progression, safety parameters, and molecular mechanisms.<BR><B>RESULTS: </B>The findings revealed a synergistic anti-HCC effect when quetiapine was coupled with RT that prolonged tumor growth time and a significantly higher growth inhibition rate compared to the control group. Safety assessments indicated minimal pathological changes, suggesting potential of quetiapine in mitigating RT-induced alterations in liver and kidney functions. Mechanistically, the combination suppressed metastasis and angiogenesis-related proteins, while triggering the activation of apoptosis-related proteins via targeting Epidermal growth factor receptor (EGFR)-mediated signaling.<BR><B>CONCLUSIONS: </B>The potential of the quetiapine and RT combination is emphasized, offering enhanced anti-HCC efficacy, a safety profile, and positioning quetiapine as a radiosensitizer for HCC treatment.